Jae‐Weon Kim
Seoul National University · 1,017 works · 22,938 citations · h-index 75
Top works
- PDGF stimulation of inositol phospholipid hydrolysis requires PLC-γ1 phosphorylation on tyrosine residues 783 and 1254
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
- A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms
- Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer
- The Reliability and Validity of Kiddie-Schedule for Affective Disorders and Schizophrenia-Present and Lifetime Version- Korean Version (K-SADS-PL-K)
- Molecular Cloning and Expression of a Complementary DNA for Inositol 1,4,5-Trisphosphate 3-Kinase
- Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer
- Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early-Stage Endometrial Cancer
- Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
- Anchorage-independent cell growth signature identifies tumors with metastatic potential
- Clinical Trials in Recurrent Ovarian Cancer
- Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002)
- Methylation of RUNX3 in various types of human cancers and premalignant stages of gastric carcinoma
- Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20.
- Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial
- Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions
- Augmentation of tumor metastasis by platelet-activating factor.
- Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial
- Neutrophil to lymphocyte ratio for preoperative diagnosis of uterine sarcomas: A case-matched comparison